Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants

Allogene Therapeutics, Inc.

Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.
Replaces David Chang and Jack Chen as interim principal financial and accounting officers.
Prior roles: COO/CFO of Tricida, CFO of Anacor (acquired by Pfizer for $5.2B), MD at Goldman Sachs.
Compensation: $490K base salary, 45% target bonus, stock option for 950K shares, RSU for 400K shares.
Performance RSU of 390K shares vests upon $18.00 share price or first FDA product approval by 2026/2028.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Geoffrey Parker

Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2023-10-16
Filed: October 17, 2023, 7:59 PM ET

appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023

Role change

David M. Chang

Interim Principal Financial Officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2023-10-16
Filed: October 17, 2023, 7:59 PM ET

replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.

Role change

Jack Chen

Interim Principal Accounting Officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2023-10-16
Filed: October 17, 2023, 7:59 PM ET

replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..

Action: appointed
Role: Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

Exact text from the filing

appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David M. Chang changed role as Interim Principal Financial Officer at Allogene Therapeutics, Inc..

Action: replaced
Role: Interim Principal Financial Officer

Exact text from the filing

replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jack Chen changed role as Interim Principal Accounting Officer at Allogene Therapeutics, Inc..

Action: replaced
Role: Interim Principal Accounting Officer

Exact text from the filing

replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.